<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559481</url>
  </required_header>
  <id_info>
    <org_study_id>I 93506</org_study_id>
    <secondary_id>RPCI-I-93506</secondary_id>
    <nct_id>NCT00559481</nct_id>
  </id_info>
  <brief_title>Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy</brief_title>
  <official_title>Effect of Oral Ketoconazole on the Pharmacokinetics of Oral Dexamethasone and Oral Hydrocortisone in Patients With Androgen Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving&#xD;
      ketoconazole together with dexamethasone and hydrocortisone may help doctors learn more about&#xD;
      how these drugs are used by the body.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying how ketoconazole, dexamethasone, and&#xD;
      hydrocortisone act in the body of patients with prostate cancer that did not respond to&#xD;
      androgen-deprivation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the pharmacokinetics of oral dexamethasone with and without oral&#xD;
           ketoconazole in patients with androgen-independent prostate cancer.&#xD;
&#xD;
        -  To compare the pharmacokinetics of oral hydrocortisone with and without oral&#xD;
           ketoconazole in these patients.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral dexamethasone twice daily on days 1-14, oral ketoconazole 3&#xD;
           times daily on days 2-14 and 30-42, and oral hydrocortisone twice daily on days 29-42.&#xD;
&#xD;
        -  Arm II: Patients receive oral hydrocortisone twice daily on days 1-14, oral ketoconazole&#xD;
           3 times daily on days 2-14 and 30-42, and oral dexamethasone twice daily on days 29-42.&#xD;
&#xD;
      In both arms, patients may receive ketoconazole and hydrocortisone as standard salvage&#xD;
      therapy off study.&#xD;
&#xD;
      In both arms, patients undergo blood sample collection on days 1, 14, 29, and 42 for&#xD;
      pharmacokinetic studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn due to low accrual&#xD;
  </why_stopped>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of oral dexamethasone with and without oral ketoconazole</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of oral hydrocortisone with and without oral ketoconazole</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic hydrocortisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis of prostate cancer&#xD;
&#xD;
          -  Must have failed standard androgen-deprivation therapy&#xD;
&#xD;
               -  Evidence of rising PSA&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Creatinine â‰¤ 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 4 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  No active congestive heart failure&#xD;
&#xD;
          -  No allergy to ketoconazole, dexamethasone, hydrocortisone, or to one of the components&#xD;
             of dexamethasone, hydrocortisone, or ketoconazole&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No uncontrolled glaucoma&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 2 weeks since prior and no concurrent drugs known to interact with study&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald L. Trump, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 15, 2007</study_first_submitted>
  <study_first_submitted_qc>November 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

